Cargando…
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
BACKGROUND: Deciding when to biopsy a man with non-suspicious DRE findings and tPSA in the 4–10 ng/ml range can be challenging, because two-thirds of such biopsies are typically found to be benign. The Prostate Health Index (phi) exhibits significantly improved diagnostic accuracy for prostate cance...
Autores principales: | White, Jay, Shenoy, B. Vittal, Tutrone, Ronald F., Karsh, Lawrence I., Saltzstein, Daniel R., Harmon, William J., Broyles, Dennis L., Roddy, Tamra E., Lofaro, Lori R., Paoli, Carly J., Denham, Dwight, Reynolds, Mark A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895603/ https://www.ncbi.nlm.nih.gov/pubmed/29158509 http://dx.doi.org/10.1038/s41391-017-0008-7 |
Ejemplares similares
-
Second Reply to Letter to the Editor re: “Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting”
por: White, Jay, et al.
Publicado: (2019) -
Elevated Prostate Health Index (phi) and Biopsy Reclassification During Active Surveillance of Prostate Cancer
por: Andreas, Darian, et al.
Publicado: (2016) -
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023) -
Beyond penile cancer, is there a role for sentinel node biopsy in urological malignancies?
por: Brouwer, O. R., et al.
Publicado: (2016) -
$Bs \to J/\Psi \phi$ and $Bs \to \phi \phi$ at LHCb
por: Leroy, Olivier
Publicado: (2009)